Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MaxCyte ( (MXCT) ) has shared an update.
MaxCyte, Inc. has announced a shift in its major holdings, with BlackRock, Inc., a significant shareholder, adjusting its voting rights in the company. BlackRock’s holdings now represent 8.44% of MaxCyte’s total voting rights. This change could potentially influence MaxCyte’s strategic decisions and impact its market positioning as it continues to innovate in the biotechnology sector.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies. The company is known for its proprietary cell engineering platform used in the development of cell-based medicines, aiming to enhance cell therapies and accelerate drug development across the market.
YTD Price Performance: -10.64%
Average Trading Volume: 44,487
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £345.1M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.
